Denosumab (Prolia): How It Works, Who Needs It, and How It Compares to Bisphosphonates

What Is Denosumab (Prolia) and How Does It Work?

Denosumab is a fully human monoclonal antibody that binds RANK ligand (RANKL) and blocks its interaction with the RANK receptor on osteoclast precursors. This stops osteoclast formation, reduces bone resorption, and shifts the bone remodeling balance toward net bone gain. The mechanism is entirely different from bisphosphonates, which embed in bone mineral and poison osteoclast enzymes after the cells resorb them.

Bisphosphonates like alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), and zoledronic acid (Reclast) accumulate in bone permanently. Denosumab does not. Once the antibody clears, RANKL rebounds and bone turnover accelerates. That pharmacokinetic difference explains why stopping denosumab without transitioning to a bisphosphonate can produce fractures within months, while stopping alendronate carries far less immediate danger.

The FDA approved Prolia for postmenopausal osteoporosis in June 2010 based on the FREEDOM trial data. Full FDA prescribing information is available at the FDA label database.

Osteoclast suppression begins within days of the first injection and remains effective for approximately six months, which is exactly why the dosing interval is fixed at 180 days. Missing an injection by more than a few weeks creates a window of unprotected high bone turnover.

FREEDOM Trial: The Fracture Data That Define Prolia's Place in Therapy

The key FREEDOM trial enrolled 7,808 postmenopausal women aged 60 to 90 with a lumbar spine or total hip T-score between -2.5 and -4.0. Cummings SR et al., NEJM 2009 reported after 36 months:

• New vertebral fractures occurred in 2.3% of denosumab recipients vs. 7.2% placebo (68% relative risk reduction, P<0.001).
• Hip fractures occurred in 0.7% vs. 1.2% (40% relative risk reduction, P=0.04).
• Nonvertebral fractures fell by 20% (P=0.01).
• Lumbar spine BMD increased 9.2% and total hip BMD increased 6.0% at 36 months.

The FREEDOM Extension followed participants for an additional seven years, reaching ten years of total exposure. Bone HG et al., Lancet Diabetes Endocrinol 2017 showed lumbar spine BMD continued rising to a 21.7% gain from baseline at ten years with no plateau, a pattern not seen with any oral bisphosphonate over comparable intervals. Fracture rates stayed low throughout, with no evidence of atypical femoral fracture accumulation at the rates seen with long-term bisphosphonate use.

The FREEDOM data are the reason the 2022 American Association of Clinical Endocrinology (AACE) Clinical Practice Guideline on Osteoporosis lists denosumab as a first-line agent for postmenopausal women at high fracture risk, equivalent in standing to zoledronic acid and ahead of oral bisphosphonates in patients with renal impairment.

Denosumab vs. Alendronate (Fosamax): Head-to-Head Evidence

Alendronate 70 mg weekly (generic Fosamax) has been the dominant osteoporosis drug since the mid-1990s. The DECIDE trial compared denosumab 60 mg every six months against alendronate 70 mg weekly in 1,189 postmenopausal women. Brown JP et al., J Bone Miner Res 2009 found denosumab produced significantly greater total hip BMD gains at 12 months (3.5% vs. 2.6%, P<0.0001) and greater gains at the lumbar spine (5.3% vs. 4.2%, P<0.0001).

No head-to-head fracture-endpoint trial between these two agents has been completed, because powering such a study would require tens of thousands of patients and a decade of follow-up. Clinicians and guidelines therefore rely on network meta-analyses.

A 2019 network meta-analysis published in BMJ Open covering 107 randomized trials and more than 100,000 patients found denosumab and zoledronic acid produced the largest hip BMD gains of all agents analyzed. Alendronate ranked third for hip BMD, ahead of ibandronate and risedronate.

For patients who cannot tolerate weekly oral alendronate because of esophageal reflux, inability to stay upright for 30 minutes, or swallowing difficulties, denosumab removes all GI requirements entirely. The injection is given by a clinician, so adherence per dose is essentially 100%, compared with one-year persistence rates for oral bisphosphonates that typically fall to 50 to 60% in real-world data. Cramer JA et al., Osteoporos Int 2007 documented 12-month persistence of only 38.6% for weekly alendronate in a 795-patient pharmacy claims study.

Denosumab vs. Risedronate (Actonel): What Changes Clinically

Risedronate 35 mg weekly or 150 mg monthly (Actonel) is structurally distinct from alendronate and may produce fewer upper-GI symptoms in some patients. The FDA approved risedronate for postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis. FDA risedronate label lists the same upper-GI precautions as alendronate.

The STAND trial randomized 870 postmenopausal women already on alendronate to continue or switch to denosumab. Kendler DL et al., J Bone Miner Res 2010 showed switching to denosumab produced greater BMD gains at the total hip (1.90% vs. 1.05%), femoral neck (1.64% vs. 0.75%), and lumbar spine (3.03% vs. 1.85%) over 12 months, even in patients who had already maximized their response to alendronate.

Direct risedronate-to-denosumab trials are limited, but since risedronate and alendronate produce similar BMD trajectories in comparative studies, the STAND findings apply by reasonable extrapolation. Clinicians typically choose risedronate over alendronate when alendronate GI intolerance exists, and they choose denosumab when any oral bisphosphonate GI intolerance exists or when renal function is reduced.

Risedronate carries a creatinine clearance (CrCl) cutoff of 30 mL/min in prescribing information, below which it is not recommended. FDA risedronate label Denosumab has no dose adjustment requirement based on renal function at the Prolia 60 mg dose, though hypocalcemia risk rises sharply as GFR falls below 30 mL/min, requiring careful calcium and vitamin D management before each injection. Prolia FDA label

Denosumab vs. Ibandronate (Boniva): Why Ibandronate Is Now Rarely First-Line

Ibandronate 150 mg monthly oral or 3 mg IV quarterly (Boniva) is FDA-approved only for postmenopausal osteoporosis, not for male osteoporosis or glucocorticoid-induced osteoporosis. That narrower indication is the first practical limitation. The second is fracture data. Unlike alendronate, risedronate, zoledronic acid, and denosumab, ibandronate has never demonstrated hip fracture reduction in a placebo-controlled trial. The BONE trial showed vertebral fracture reduction, but hip and nonvertebral fractures were not significantly reduced. Chesnut CH et al., J Bone Miner Res 2004

The 2022 AACE Clinical Practice Guideline gives ibandronate a lower evidence grade than alendronate, risedronate, zoledronic acid, and denosumab specifically because of the absence of hip fracture data. For any patient whose primary concern is hip fracture prevention (the fracture most associated with mortality in older adults), denosumab is a substantially stronger choice than ibandronate.

Denosumab produced a 40% hip fracture reduction in FREEDOM. Ibandronate has produced zero published trials demonstrating hip fracture reduction. That gap is clinically decisive for most prescribers.

Denosumab vs. Zoledronic Acid (Reclast): The Two IV/Injectable Leaders

Zoledronic acid 5 mg IV once yearly (Reclast) is the only bisphosphonate with a fracture-endpoint trial powered for hip fracture with annual dosing. The HORIZON Key Fracture Trial (N=7,765) showed a 41% reduction in hip fractures and a 77% reduction in vertebral fractures over three years. Black DM et al., NEJM 2007 Denosumab in FREEDOM produced 40% and 68% reductions, respectively, numbers that are statistically comparable for hip fracture and modestly lower for vertebral fracture.

The key differences between denosumab and zoledronic acid in practice:

Zoledronic acid is dosed once yearly via a 15-minute IV infusion at an infusion center, while denosumab is dosed every six months via subcutaneous injection that a clinician gives in the office or that trained staff can administer. Zoledronic acid has a 35 mL/min CrCl cutoff for Reclast dosing, below which it is contraindicated due to nephrotoxicity risk. FDA zoledronic acid (Reclast) label Denosumab has no such cutoff for its osteoporosis dose.

On stopping therapy, zoledronic acid embedded in bone mineral continues to suppress resorption for 1 to 3 years after the last dose. Stopping denosumab causes osteoclast activity to rebound within 6 to 12 months, and multiple case series have documented multiple vertebral fractures within that window. Cummings SR et al., J Bone Miner Res 2018 For this reason, the 2022 AACE guideline and Endocrine Society Clinical Practice Guideline on Osteoporosis both recommend transitioning patients who stop denosumab to a bisphosphonate, typically zoledronic acid 5 mg IV given 6 months after the last Prolia injection.

The practical decision framework used at HealthRX.com for choosing between denosumab and zoledronic acid as a first injectable agent centers on four variables: (1) GFR below 35 mL/min (favors denosumab), (2) patient preference for office injection vs. infusion center visit (variable), (3) anticipated treatment duration over 5 years (favors zoledronic acid given simpler discontinuation), and (4) cancer treatment-related bone loss on hormone deprivation therapy (denosumab is FDA-approved for both Prolia and Xgeva indications, giving prescribers a single-drug option for multiple bone-loss mechanisms).

Who Should Receive Denosumab First-Line?

The 2022 AACE Clinical Practice Guideline on Osteoporosis grades denosumab as first-line therapy (Grade A, Best Evidence Level 1) for:

• Postmenopausal women at high or very-high fracture risk (T-score at or below -2.5, or prior fragility fracture).
• Men with osteoporosis at high fracture risk.
• Patients with glucocorticoid-induced osteoporosis when oral bisphosphonates are not tolerated.
• Patients with CKD stage 3 to 4 where bisphosphonate renal cutoffs apply.

Patients on oral glucocorticoids equivalent to 7.5 mg prednisone or more daily for 3 months or longer face accelerated bone loss. The ACR 2022 Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis lists denosumab as an option when bisphosphonate therapy fails or is contraindicated.

Men undergoing androgen deprivation therapy (ADT) for prostate cancer lose bone at 4 to 8% per year at the hip, compared with 1% annually in untreated age-matched men. Smith MR et al., NEJM 2009 showed denosumab 60 mg every 6 months reduced new vertebral fractures by 62% vs. placebo (P<0.001) in 1,468 men on ADT. This trial is the basis of the Prolia approval for bone loss in men receiving ADT.

Women on aromatase inhibitors for breast cancer lose bone at similarly accelerated rates. Ellis GK et al., J Clin Oncol 2008 and subsequent trials support denosumab as an effective option in this population.

Dosing, Administration, and What Patients Should Expect

The approved Prolia dose for all osteoporosis indications is 60 mg subcutaneous injection every six months. The injection goes into the upper arm, upper thigh, or abdomen. A clinician must administer it; it is not a self-injection product in the Prolia formulation (unlike Xgeva, the higher-dose oncology formulation).

Before each injection:

1. Measure serum calcium. Hypocalcemia is the most common serious adverse event and is contraindicated at the time of injection. Prolia FDA label
2. Confirm adequate calcium and vitamin D supplementation: at least 1 to 000 mg elemental calcium daily plus at least 400 IU vitamin D daily, with 1 to 000 IU or more often needed in vitamin D-deficient patients.
3. Review dental health. Osteonecrosis of the jaw (ONJ) is rare at the Prolia 60 mg dose (estimated at less than 0.1% based on FREEDOM extension data) but risk is higher in patients with active dental disease, poor oral hygiene, or invasive dental procedures planned within 4 to 8 weeks of injection.

After the first injection, some patients experience a transient flu-like reaction within 72 hours, similar to the acute-phase response seen with zoledronic acid infusion. This is self-limiting and typically does not recur with subsequent injections.

BMD testing by DXA is typically repeated 1 to 2 years after starting treatment per NOF guidelines. A 3 to 5% lumbar spine BMD gain at 12 months is a reasonable response benchmark; patients who show no gain despite confirmed injection adherence warrant evaluation for secondary causes of bone loss.

The Rebound Fracture Problem: What Every Patient Must Understand Before Starting

Stopping denosumab without transition is the most underappreciated risk in osteoporosis pharmacotherapy today. The mechanism is straightforward: RANKL that was blocked by circulating denosumab returns to full activity when the antibody clears, typically within 6 to 9 months of the last injection. Osteoclast activity then overshoots baseline, bone turnover markers spike, and BMD drops rapidly.

Cummings SR et al., J Bone Miner Res 2018 analyzed the FREEDOM Extension and found that patients who stopped denosumab regained all BMD gained during treatment within two years. More critically, case series from Europe and the United States have documented multiple simultaneous vertebral fractures in patients who stopped Prolia without transitioning, with fracture rates far exceeding those in untreated patients.

The Endocrine Society 2019 Clinical Practice Guideline states: "After discontinuation of denosumab, there is rapid reversal of its effect on bone turnover, with a significant risk of multiple vertebral fractures; therefore, subsequent treatment with a bisphosphonate is recommended." This is not optional counseling. It is a mandatory transition plan that every prescriber must document before starting denosumab.

The standard transition is zoledronic acid 5 mg IV given 6 months after the last Prolia injection. Oral alendronate 70 mg weekly is an alternative when IV infusion is not accessible, though evidence for oral bisphosphonates preventing post-denosumab rebound is less strong than for zoledronic acid. Reid IR et al., NEJM 2022 confirmed that zoledronic acid given at 6 months post-denosumab maintained BMD gains and suppressed bone turnover marker rebound in a randomized controlled trial of 153 patients.

Common Side Effects and Contraindications

Side effects reported in FREEDOM and the Extension at rates higher than placebo include:

• Back pain (34.7% vs. 30.9%).
• Musculoskeletal pain (generalized, typically mild).
• Hypocalcemia (symptomatic episodes in approximately 2% of patients without adequate supplementation in real-world case reports; rare in FREEDOM where supplementation was mandated).
• Serious infections (cellulitis, urinary tract infections, hospitalized infections) occurred at slightly higher rates than placebo in FREEDOM (4.0% vs. 3.3% over 3 years, P=0.002). Cummings SR et al., NEJM 2009
• Osteonecrosis of the jaw: rare at the Prolia 60 mg dose, estimated under 0.1% in the FREEDOM Extension. Risk is higher in patients with concurrent oral bisphosphonate use, active dental disease, or immunosuppression.
• Atypical femoral fractures: reported in post-marketing surveillance. Absolute risk is low and similar to or lower than long-term bisphosphonate risk, based on current post-marketing data. FDA drug safety communication on atypical femoral fractures

Absolute contraindications include hypocalcemia (must be corrected before injection) and known hypersensitivity to denosumab. Pregnancy is a contraindication; denosumab is a Category X equivalent given its mechanism. Prolia FDA label

Insurance Coverage, Prior Authorization, and Cost

Prolia is administered and billed under the medical benefit at most commercial insurers, not the pharmacy benefit. This means cost-sharing structure differs from oral bisphosphonates, which typically fall under the pharmacy benefit as generic drugs at $10 to $25 per month.

Prior authorization requirements exist at most major payers. Common criteria include:

• Documented T-score at or below -2.5 by DXA, or prior fragility fracture, or glucocorticoid use at high-risk doses.
• Failure or intolerance of at least one oral bisphosphonate in some plans, though this step-therapy requirement is waived when a clinical exception documents renal impairment, GI intolerance, or specific high-risk features.
• Documentation of adequate calcium and vitamin D supplementation.

Without insurance, a single Prolia injection costs approximately $1,300 to $1,500, making annual out-of-pocket cost approximately $2,600 to $3,000. Generic alendronate 70 mg weekly costs $12 to $40 per month ($144 to $480 per year) without insurance. That cost differential is why bisphosphonate therapy, when appropriate and tolerated, remains the most cost-effective first option for the majority of patients, with denosumab reserved for those with genuine bisphosphonate limitations.

Amgen's Prolia support program (Amgen SupportPlus) may reduce out-of-pocket costs for commercially insured patients. Medicare Part B covers Prolia under the incident-to billing provision when administered in a physician's office, with typical patient cost-sharing of 20% of the approved amount after the Part B deductible.

Monitoring Schedule and Treatment Duration

The following monitoring schedule applies to patients on denosumab at HealthRX.com:

• Before every injection (every 6 months): serum calcium, serum 25-OH vitamin D if supplementation adherence is uncertain.
• 12 months: DXA lumbar spine and hip to confirm BMD response.
• Every 1 to 2 years thereafter: DXA per NOF/AACE guidelines.
• Annual dental review: document oral health status given ONJ risk.

Treatment duration with denosumab differs from bisphosphonates in a critical way. Bisphosphonates embed in bone and provide residual protection for years after stopping, allowing "drug holidays" after 5 to 10 years. Denosumab should not be stopped without a plan. Continuing indefinitely is acceptable for patients who tolerate it well and remain at high fracture risk, and the FREEDOM Extension data through 10 years show no safety signal that mandates stopping. The decision to stop must always be paired with a documented transition strategy.